Will the FDA approve baxdrostat for hard-to-control hypertension?

Prediction market on kalshi. If the FDA approves baxdrostat for hard-to-control hypertension for marketing before Jun 1, 2026, then the market resolves to Yes.

24h Volume: $3,536.21. Liquidity: $3,113.21. Resolves: 6/8/2026.